Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Steinbach

Showing results (241-250 of 369) with videos related to

Pageof 37
Sort By:
Faraday Discussions|March 18, 2011
Spiers Memorial Lecture. Breeding and building molecular spiesX Shu, V Lev-Ram, E S Olson, et al.
Cancer & Metabolism|April 18, 2026
In vivo characterization of the redox balance in IDH-wildtype glioblastomas: a J-difference edited MEGA-sLASER MRS study at 3TSeyma Alcicek, Andrei Manzhurtsev, Dennis C Thomas, et al.
Brain : a Journal of Neurology|October 4, 2017
Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell deathAnna-Luisa Thiepold, Nadja I Lorenz, Martha Foltyn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 26, 2020
Sequential implementation of DSC-MR perfusion and dynamic [<sup>18</sup>F]FET PET allows efficient differentiation of glioma progression from treatment-related changesEike Steidl, Karl-Josef Langen, Sarah Abu Hmeidan, et al.
Acta Neuropathologica|May 9, 2019
Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomasKatharina Filipski, Yannick Braun, Jenny Zinke, et al.
Plos One|March 21, 2014
Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastasesPatrick N Harter, Jenny Zinke, Alexander Scholz, et al.
Neurology|December 22, 2010
Complementary therapy use in patients with glioma: an observational studyO Heese, M Schmidt, S Nickel, et al.
Journal of Neuro-Oncology|May 20, 2016
Prognostic factors in recurrent glioblastoma patients treated with bevacizumabChristina Schaub, Julia Tichy, Niklas Schäfer, et al.
Oncology Reports|October 18, 2017
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal diseaseMichael C Burger, Michael W Ronellenfitsch, Nadja I Lorenz, et al.
Neuro-Oncology|December 3, 2015
Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomasPeter Baumgarten, Anna-Eva Blank, Kea Franz, et al.
Pageof 37

Showing results (241-250 of 369) with videos related to

Sort By:
Pageof 37
Faraday Discussions|March 18, 2011
Spiers Memorial Lecture. Breeding and building molecular spiesX Shu, V Lev-Ram, E S Olson, et al.
Cancer & Metabolism|April 18, 2026
In vivo characterization of the redox balance in IDH-wildtype glioblastomas: a J-difference edited MEGA-sLASER MRS study at 3TSeyma Alcicek, Andrei Manzhurtsev, Dennis C Thomas, et al.
Brain : a Journal of Neurology|October 4, 2017
Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell deathAnna-Luisa Thiepold, Nadja I Lorenz, Martha Foltyn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 26, 2020
Sequential implementation of DSC-MR perfusion and dynamic [<sup>18</sup>F]FET PET allows efficient differentiation of glioma progression from treatment-related changesEike Steidl, Karl-Josef Langen, Sarah Abu Hmeidan, et al.
Acta Neuropathologica|May 9, 2019
Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomasKatharina Filipski, Yannick Braun, Jenny Zinke, et al.
Plos One|March 21, 2014
Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastasesPatrick N Harter, Jenny Zinke, Alexander Scholz, et al.
Neurology|December 22, 2010
Complementary therapy use in patients with glioma: an observational studyO Heese, M Schmidt, S Nickel, et al.
Journal of Neuro-Oncology|May 20, 2016
Prognostic factors in recurrent glioblastoma patients treated with bevacizumabChristina Schaub, Julia Tichy, Niklas Schäfer, et al.
Oncology Reports|October 18, 2017
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal diseaseMichael C Burger, Michael W Ronellenfitsch, Nadja I Lorenz, et al.
Neuro-Oncology|December 3, 2015
Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomasPeter Baumgarten, Anna-Eva Blank, Kea Franz, et al.
Pageof 37